Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate

Y. Kanda, K. Izutsu, H. Hirai, H. Sakamaki, T. Iseki, Y. Kodera, Shinichiro Okamoto, H. Mitsui, K. Iwato, N. Hirabayashi, T. Furukawa, A. Maruta, M. Kasai, Y. Atsuta, N. Hamajima, A. Hiraoka, K. Kawa

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24%) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47%) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.

Original languageEnglish
Pages (from-to)1013-1019
Number of pages7
JournalLeukemia
Volume18
Issue number5
DOIs
Publication statusPublished - 2004 May

Fingerprint

Graft vs Host Disease
Bone Marrow Transplantation
Methotrexate
Cyclosporine
Siblings
Tissue Donors
Recurrence
Incidence
Transplantation
Transplants
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Disease-Free Survival
Bone Marrow
Survival
Mortality

Keywords

  • Bone marrow transplantation
  • Graft-versus-host disease
  • Graft-versus-leukemia effect

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. / Kanda, Y.; Izutsu, K.; Hirai, H.; Sakamaki, H.; Iseki, T.; Kodera, Y.; Okamoto, Shinichiro; Mitsui, H.; Iwato, K.; Hirabayashi, N.; Furukawa, T.; Maruta, A.; Kasai, M.; Atsuta, Y.; Hamajima, N.; Hiraoka, A.; Kawa, K.

In: Leukemia, Vol. 18, No. 5, 05.2004, p. 1013-1019.

Research output: Contribution to journalArticle

Kanda, Y, Izutsu, K, Hirai, H, Sakamaki, H, Iseki, T, Kodera, Y, Okamoto, S, Mitsui, H, Iwato, K, Hirabayashi, N, Furukawa, T, Maruta, A, Kasai, M, Atsuta, Y, Hamajima, N, Hiraoka, A & Kawa, K 2004, 'Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate', Leukemia, vol. 18, no. 5, pp. 1013-1019. https://doi.org/10.1038/sj.leu.2403343
Kanda, Y. ; Izutsu, K. ; Hirai, H. ; Sakamaki, H. ; Iseki, T. ; Kodera, Y. ; Okamoto, Shinichiro ; Mitsui, H. ; Iwato, K. ; Hirabayashi, N. ; Furukawa, T. ; Maruta, A. ; Kasai, M. ; Atsuta, Y. ; Hamajima, N. ; Hiraoka, A. ; Kawa, K. / Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. In: Leukemia. 2004 ; Vol. 18, No. 5. pp. 1013-1019.
@article{478fc8b7cad74dc79fbf6d8bf932e45e,
title = "Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate",
abstract = "The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24{\%}) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47{\%}) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.",
keywords = "Bone marrow transplantation, Graft-versus-host disease, Graft-versus-leukemia effect",
author = "Y. Kanda and K. Izutsu and H. Hirai and H. Sakamaki and T. Iseki and Y. Kodera and Shinichiro Okamoto and H. Mitsui and K. Iwato and N. Hirabayashi and T. Furukawa and A. Maruta and M. Kasai and Y. Atsuta and N. Hamajima and A. Hiraoka and K. Kawa",
year = "2004",
month = "5",
doi = "10.1038/sj.leu.2403343",
language = "English",
volume = "18",
pages = "1013--1019",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate

AU - Kanda, Y.

AU - Izutsu, K.

AU - Hirai, H.

AU - Sakamaki, H.

AU - Iseki, T.

AU - Kodera, Y.

AU - Okamoto, Shinichiro

AU - Mitsui, H.

AU - Iwato, K.

AU - Hirabayashi, N.

AU - Furukawa, T.

AU - Maruta, A.

AU - Kasai, M.

AU - Atsuta, Y.

AU - Hamajima, N.

AU - Hiraoka, A.

AU - Kawa, K.

PY - 2004/5

Y1 - 2004/5

N2 - The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24%) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47%) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.

AB - The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24%) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47%) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.

KW - Bone marrow transplantation

KW - Graft-versus-host disease

KW - Graft-versus-leukemia effect

UR - http://www.scopus.com/inward/record.url?scp=2342451871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342451871&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403343

DO - 10.1038/sj.leu.2403343

M3 - Article

C2 - 15029208

AN - SCOPUS:2342451871

VL - 18

SP - 1013

EP - 1019

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -